Loading
CellsBin
CellsBin, in Connecticut, makes instruments that find extremely rare cells in a blood sample. One is being developed to follow multiple myeloma from blood instead of repeated bone marrow biopsies.
Also called: CellsBin, Inc.
Overview
CellsBin, Inc. develops rare-cell detection and single-cell profiling platforms, sold for research use only. Its Scout product detects and profiles rare therapeutic cells such as CAR-T cells in circulation, and Insight is being developed for blood-based assessment of multiple myeloma, from detection and longitudinal monitoring to risk stratification. A 2026 National Cancer Institute SBIR award funds the detection and isolation of circulating myeloma cells towards a minimally invasive CLIA-certified test; the award abstract describes Insight as combining high-resolution imaging, microfluidics and machine learning.
Headquarters
Branford, CT, US
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR (R44) award 1R44CA314758-01: Detection and Isolation of Circulating Myeloma Cells: Toward a Minimally-Invasive CLIA-Certified Diagnostic for Multiple Myeloma | 2026 | $1M | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Notes
- Company website and the NIH RePORTER record read on 4 November 2026. Its products are labelled research use only on the website.
Connected
3Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
cellsbin.com · 1
nih.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/